中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
19期
37-37,38
,共2页
杨宏昕%董珉翔%米裕青%白音夫
楊宏昕%董珉翔%米裕青%白音伕
양굉흔%동민상%미유청%백음부
肝纤维化%免疫组化%基质金属蛋白酶-1%基质金属蛋白酶抑制因子-1
肝纖維化%免疫組化%基質金屬蛋白酶-1%基質金屬蛋白酶抑製因子-1
간섬유화%면역조화%기질금속단백매-1%기질금속단백매억제인자-1
liver fibrosis%ELISA%MMP-1%TIMP-1
目的:探讨蒙古山萝卜酸对肝纤维化大鼠血清基质金属蛋白酶原-1(MMP-1)与基质金属蛋白酶抑制因子(TIMP-1)表达水平的影响。方法将50只大鼠(雌雄各半)分为对照组、模型组、阳性对照组(秋水仙碱1.5 mg/kg)以及试验药物高剂量组、低剂量组(蒙古山萝卜酸240 mg/kg和30 mg/kg),每组10只。除对照组外,皮下注射给药,含25%CCl4的花生油1 mL/kg,每隔4 d注射1次,共计30次。第4次注射后,阳性对照组及试验药物高、低剂量组开始灌胃给药,1次/d。分次与30次注射后,麻醉剖腹,腹主动脉采血,分离血清,ELISA法测定。结果对照组血清MMP-1及TIMP-1有少量表达;模型组MMP-1表达水平明显降低,TIMP-1表达水平显著升高( P<0.05);阳性药对照组MMP-1没有明显改变,TIMP-1表达水平显著降低( P<0.05);试验药物高剂量组MMP-1表达水平明显上升、TIMP-1表达水平显著降低( P<0.05);试验药物低剂量组MMP-1及TIMP-1无明显变化。结论蒙古山萝卜酸参与大鼠抗肝纤维化MMP-1/TIMP-1表达水平失衡的调节作用,是防治肝纤维化作用机理之一。
目的:探討矇古山蘿蔔痠對肝纖維化大鼠血清基質金屬蛋白酶原-1(MMP-1)與基質金屬蛋白酶抑製因子(TIMP-1)錶達水平的影響。方法將50隻大鼠(雌雄各半)分為對照組、模型組、暘性對照組(鞦水仙堿1.5 mg/kg)以及試驗藥物高劑量組、低劑量組(矇古山蘿蔔痠240 mg/kg和30 mg/kg),每組10隻。除對照組外,皮下註射給藥,含25%CCl4的花生油1 mL/kg,每隔4 d註射1次,共計30次。第4次註射後,暘性對照組及試驗藥物高、低劑量組開始灌胃給藥,1次/d。分次與30次註射後,痳醉剖腹,腹主動脈採血,分離血清,ELISA法測定。結果對照組血清MMP-1及TIMP-1有少量錶達;模型組MMP-1錶達水平明顯降低,TIMP-1錶達水平顯著升高( P<0.05);暘性藥對照組MMP-1沒有明顯改變,TIMP-1錶達水平顯著降低( P<0.05);試驗藥物高劑量組MMP-1錶達水平明顯上升、TIMP-1錶達水平顯著降低( P<0.05);試驗藥物低劑量組MMP-1及TIMP-1無明顯變化。結論矇古山蘿蔔痠參與大鼠抗肝纖維化MMP-1/TIMP-1錶達水平失衡的調節作用,是防治肝纖維化作用機理之一。
목적:탐토몽고산라복산대간섬유화대서혈청기질금속단백매원-1(MMP-1)여기질금속단백매억제인자(TIMP-1)표체수평적영향。방법장50지대서(자웅각반)분위대조조、모형조、양성대조조(추수선감1.5 mg/kg)이급시험약물고제량조、저제량조(몽고산라복산240 mg/kg화30 mg/kg),매조10지。제대조조외,피하주사급약,함25%CCl4적화생유1 mL/kg,매격4 d주사1차,공계30차。제4차주사후,양성대조조급시험약물고、저제량조개시관위급약,1차/d。분차여30차주사후,마취부복,복주동맥채혈,분리혈청,ELISA법측정。결과대조조혈청MMP-1급TIMP-1유소량표체;모형조MMP-1표체수평명현강저,TIMP-1표체수평현저승고( P<0.05);양성약대조조MMP-1몰유명현개변,TIMP-1표체수평현저강저( P<0.05);시험약물고제량조MMP-1표체수평명현상승、TIMP-1표체수평현저강저( P<0.05);시험약물저제량조MMP-1급TIMP-1무명현변화。결론몽고산라복산삼여대서항간섬유화MMP-1/TIMP-1표체수평실형적조절작용,시방치간섬유화작용궤리지일。
Objective To investigate the effect of Mongolia scabious acid ( MSA ) on the expression levels of serum matrix metalloproteinas-es-1 ( MMP-1 ) and tissue inhibitor of metalloproteinases-1 ( TIMP-1 ) in the experimental liver fibrosis rats. Methods 50 rats ( male and female half ) were divided into the control group, model group, positive control group ( colchicine 1. 5 mg/kg ) and high- and low-dose groups of tested drug ( MSA 240, 30 mg/kg ) , 10 rats in each group, except the control group, 25% CCl4 peanut oil1 mL/25 kg was given by subcutaneous injection, once per 4 d with a total of 30 times. After 4 times of injection, the positive control group, high- and low-dose groups of test drug began to give the test drug by intragastric administration, once daily. After the injection of 30 times, the anesthetic laparotomy was performed and blood was collected from rat abdominal aorta for separating serum. Then the ELISA determination was performed. Results Serum MMP-1 and TIMP-1 in the model group had a small amount of expression, the MMP-1 expression level in the model group was obviously decreased and the TIMP-1 expression was significantly increased compared with the control group ( P<0. 05 );the MMP-1 expression level in the positive medication control group had no obvious change and the TIMP-1 level was signifi-cantly decreased;the MMP-1 expression level in the high-dose group of test drug was significantly increased obviously and the expres-sion level of TIMP-1 was significantly reduced compared with the model group ( P<0. 05 );the low-dose group of test drug had no ef-fects on the expression of MMP-1 and TIMP-1. Conclusion MSA participates in the anti-liver fibrosis regulating effect in imbalance of MMP-1/TIMP-1 expression level in rat, which is one of the mechanisms of prevention and treatment of liver fibrosis.